

Douglas A. Ducey, Governor Jami Snyder, Director

AHCCCS Pharmacy and Therapeutics Committee Meeting Minutes October 18, 2021 12:00PM- 5:00 PM Teleconference

Members Present:

Andrew Thatcher Stephen Borodkin Maria Cole Raul Romero Kendra Gray Yvonne Johnson Chuck Goldstein Kelly Flannigan Sandra Brownstein

AHCCCS Staff:

Suzi Berman Lauren Prole Robin Davis Susan Kennard

Magellan Medicaid Admin:

Hind Douiki

Members Absent:

Aida Amado Aimee Schwartz Craig Sparazza Loann Nguy

WELCOME AND INTRODUCTIONS: SUZI BERMAN, RPH, AHCCCS PHARMACY DIRECTOR

- 1. Suzi Berman called the meeting to order at 12:08 PM and welcomed committee members, staff and public attendees.
- 2. The meeting minutes from the January 26, 2021 meeting were reviewed.
 - a. Motion to accept:
 - i. 1st- Raul Romero
 - ii. 2nd- Andrew Thatcher
- 3. All submitted written testimony will be posted on the AHCCCS website under Pharmacy/Pharmacy & Therapeutics Committee

NON-SUPPLEMENTAL REBATE CLASS REVIEW: HIND DOUIKI, PHARMD, MAGELLAN

- 1. Antimigraine Agents Triptans
 - a. Public Testimony: None
- 2. Leukotriene Modifiers
 - a. Public Testimony: None
- 3. Sedative Hypnotics
 - a. Public Testimony: None
- 4. Topical Steroids by Potency (Low, Medium, High, Very High)
 - a. Public Testimony: None
- 5. Antifungals Oral
 - a. Public Testimony: None
- 6. Antifungals Topicals
 - a. Public Testimony: None
- 7. Beta Blockers
 - a. Public Testimony: None
- 8. BPH Treatments
 - a. Public Testimony: None
- 9. Calcium Channel Blockers
 - a. Public Testimony: None

10. Movement Disorders

a. Public Testimony: None

11. HIV-AIDS

.

a. Public Testimony: None

SUPPLEMENTAL REBATE CLASS REVIEW: HIND DOUIKI, PHARMD, MAGELLAN

Continuous Glucose Monitors (CGM)

 Public Testimony: None

New Drug Reviews: HIND DOUIKI, PHARMD, MAGELLAN

	Brand Name	<u>Generic Name</u>
1.	Brexafemme	Ibrexafungerp
2.	Kloxxado	Naloxone 8mg/0.1ml
3.	Ponvory	Ponesimod
4.	Qelbree	Viloxazine

P&T Requests

- Request by Dr. Kevin Chapman to allow Clonazepam ODT without PA for children < 6 years of age
 Recommendation is to remove PA on Clonazepam ODT for children < 6 years of age
 - All present committee members voted in favor of the recommendation
 - No committee members voted against the recommendations.
 - No committee members abstained.

• Request by Denise Volkov to remove prior authorization requirements for Budesonide inhalation vials

- Recommendation is to remove PA on Budesonide for all ages
 - All present committee members voted in favor of the recommendation
 - No committee members voted against the recommendations.
 - No committee members abstained.

Executive Session – Closed to the Public

Public Therapeutic Class Votes:

Non-Supplemental class vote

- 1. Antimigraine Agents-Triptans
 - a. Preferred Products
 - i. NARATRIPTAN (ORAL)
 - ii. RIZATRIPTAN ODT (ORAL)

- iii. RIZATRIPTAN TABLET (ORAL)
- iv. SUMATRIPTAN KIT (SUBCUTANE.)
- v. SUMATRIPTAN KIT (SUN) (SUBCUTANE.)
- vi. SUMATRIPTAN (ORAL)
- vii. SUMATRIPTAN VIAL (SUBCUTANE.)
- viii. ZOLMITRIPTAN ODT (ORAL)
- ix. ZOLMITRIPTAN TABLET (ORAL)
- b. Non-Preferred
 - i. ZOLMITRIPTAN ODT (AG) (ORAL)
 - ii. ZOLMITRIPTAN TABLET (AG) (ORAL)
- c. Grandfathering does not apply
- d. The committee voted on the above recommendations
 - i. All present committee members voted in favor of the recommendations
 - ii. No committee members voted against the recommendations.
 - iii. No committee members abstained.
- 2. Leukotriene Modifiers
 - a. Preferred Products
 - i. MONTELUKAST TABLET (ORAL)
 - ii. MONTELUKAST CHEWABLE TABLET (ORAL)
 - iii. MONTELUKAST GRANULES (ORAL)
 - b. Grandfathering applies
 - c. The committee voted on the above recommendations
 - i. All present committee members voted in favor of the recommendations
 - ii. No committee members voted against the recommendations.
 - iii. No committee members abstained.
- 3. Sedative Hypnotics
 - a. Preferred Products
 - i. ESZOPICLONE (ORAL)
 - ii. ROZEREM (ORAL)-Step therapy required- must try 2 other preferred products
 - iii. TEMAZEPAM (ORAL) 15 mg and 30 mg capsules
 - iv. ZOLPIDEM (ORAL)
 - b. Grandfathering applies
 - c. The committee voted on the above recommendations
 - i. All present committee members voted in favor of the recommendations
 - ii. No committee members voted against the recommendations.
 - iii. No committee members abstained.
- 4. Topical Steroids by Potency (Low, medium, High, Very High)
 - a. Preferred Products

- i. Low Potency Topical Steroid Agents
 - 1. DERMA-SMOOTHE-FS (TOPICAL)
 - 2. HYDROCORTISONE ACETATE CREAM OTC (TOPICAL)*
 - 3. HYDROCORTISONE ACETATE OINTMENT OTC (TOPICAL)*
 - 4. HYDROCORTISONE-ALOE CREAM OTC (TOPICAL)
 - 5. HYDROCORTISONE CREAM OTC (TOPICAL)*
 - 6. HYDROCORTISONE CREAM (TOPICAL)*
 - 7. HYDROCORTISONE LOTION OTC (TOPICAL)*
 - 8. HYDROCORTISONE OINTMENT OTC (TOPICAL)*
 - 9. HYDROCORTISONE OINTMENT (TOPICAL)*
- ii. Medium Potency Topical Steroid Agents
 - 1. FLUTICASONE PROPIONATE CREAM (TOPICAL)*
 - 2. FLUTICASONE PROPIONATE OINTMENT (TOPICAL)*
 - 3. MOMETASONE FUROATE CREAM (TOPICAL)*
 - 4. MOMETASONE FUROATE OINTMENT (TOPICAL)*
 - 5. MOMETASONE FUROATE SOLUTION (TOPICAL)*
- iii. High Potency Topical Steroid Agents
 - 1. BETAMETHASONE DIPROPIONATE CREAM (TOPICAL)-NEW
 - 2. BETAMETHASONE DIPROPIONATE LOTION (TOPICAL)
 - 3. BETAMET DIPROP / PROP GLY CREAM (TOPICAL)*
 - 4. BETAMETHASONE VALERATE CREAM (TOPICAL)*
 - 5. BETAMETHASONE VALERATE LOTION (TOPICAL)*
 - 6. BETAMETHASONE VALERATE OINTMENT (TOPICAL)*
 - 7. FLUOCINONIDE CREAM (TOPICAL)*
 - 8. FLUOCINONIDE OINTMENT (TOPICAL)*
 - 9. FLUOCINONIDE SOLUTION (TOPICAL)*
 - 10. TRIAMCINOLONE ACETONIDE CREAM (TOPICAL)*
 - 11. TRIAMCINOLONE ACETONIDE LOTION (TOPICAL)*
 - 12. TRIAMCINOLONE ACETONIDE OINTMENT (TOPICAL)*
- iv. Very High Potency Topical Steroid Agents
 - 1. CLOBETASOL EMOLLIENT (TOPICAL)
 - 2. CLOBETASOL PROPIONATE CREAM (TOPICAL)*
 - 3. CLOBETASOL PROPIONATE GEL (TOPICAL)*
 - 4. CLOBETASOL PROPIONATE OINTMENT (TOPICAL)*
 - 5. CLOBETASOL PROPIONATE SOLUTION (TOPICAL)*
 - 6. CLOBETASOL SHAMPOO (TOPICAL)- NEW
 - 7. HALOBETASOL PROPIONATE CREAM (TOPICAL)
 - 8. HALOBETASOL PROPIONATE OINTMENT (TOPICAL
- b. Grandfathering does not apply

- c. The committee voted on the above recommendations
 - i. All present committee members voted in favor of the recommendations
 - ii. No committee members voted against the recommendations.
 - iii. No committee members abstained.
- 5. Antifungals-Oral
 - a. Preferred products
 - i. CLOTRIMAZOLE (MUCOUS MEM)
 - ii. FLUCONAZOLE SUSPENSION (ORAL)*
 - iii. FLUCONAZOLE TABLET (ORAL)*
 - iv. GRISEOFULVIN SUSPENSION (ORAL)*
 - v. GRISEOFULVIN TABLETS (ORAL)*
 - vi. NYSTATIN SUSPENSION (ORAL)*
 - vii. NYSTATIN TABLET (ORAL)*
 - viii. TERBINAFINE (ORAL)*
 - b. Grandfathering does not apply
 - c. The committee voted on the above recommendations
 - i. All present committee members voted in favor of the recommendations
 - ii. No committee members voted against the recommendations.
 - iii. No committee members abstained.
- 6. Antifungals-Topicals
 - a. Preferred Products
 - i. CICLOPIROX CREAM (TOPICAL)
 - ii. CICLOPIROX SOLUTION (TOPICAL)
 - iii. CLOTRIMAZOLE-BETAMETHASONE CREAM (TOPICAL)*
 - iv. CLOTRIMAZOLE CREAM OTC (TOPICAL)*
 - v. CLOTRIMAZOLE CREAM RX (TOPICAL)*
 - vi. CLOTRIMAZOLE SOLUTION OTC (TOPICAL)*
 - vii. KETOCONAZOLE CREAM (TOPICAL)*
 - viii. KETOCONAZOLE SHAMPOO (TOPICAL)*
 - ix. LOTRIMIN ULTRA OTC (TOPICAL)
 - x. MICONAZOLE CREAM OTC (TOPICAL)*
 - xi. MICONAZOLE POWDER OTC (TOPICAL)*
 - xii. NYSTATIN CREAM (TOPICAL)*
 - xiii. NYSTATIN OINT (TOPICAL)*
 - xiv. NYSTATIN POWDER (TOPICAL)*
 - xv. TERBINAFINE CREAM OTC (TOPICAL)
 - xvi. TOLNAFTATE CREAM OTC (TOPICAL)
 - xvii. TOLNAFTATE POWDER OTC (TOPICAL)
 - xviii. TOLNAFTATE AERO POWDER OTC (TOPICAL)

- b. Grandfathering does not apply
- c. The committee voted on the above recommendations
 - i. All present committee members voted in favor of the recommendations
 - ii. No committee members voted against the recommendations.
 - iii. No committee members abstained.
- 7. Beta Blockers
 - a. Preferred Products
 - i. ATENOLOL (ORAL)*
 - ii. ATENOLOL / CHLORTHALIDONE (ORAL)*
 - iii. BISOPROLOL HCTZ (ORAL)
 - iv. BISOPROLOL (ORAL)
 - v. CARVEDILOL (ORAL)*
 - vi. LABETALOL (ORAL)*
 - vii. METOPROLOL / HCTZ (ORAL)
 - viii. METOPROLOL (ORAL)*
 - ix. METOPROLOL XL (ORAL)*
 - x. NADOLOL (ORAL)*
 - xi. PROPRANOLOL ER (ORAL)*
 - xii. PROPRANOLOL ER (AG) (ORAL)
 - xiii. PROPRANOLOL / HCTZ (ORAL)
 - xiv. PROPRANOLOL SOLUTION (ORAL)*
 - xv. PROPRANOLOL TABLET (ORAL)*
 - xvi. SOTALOL (ORAL)*
 - b. Grandfathering applies
 - c. The committee voted on the above recommendations
 - i. All present committee members voted in favor of the recommendations
 - ii. No committee members voted against the recommendations.
 - iii. No committee members abstained.
- 8. BPH Treatments
 - a. Preferred Products
 - i. ALFUZOSIN (ORAL)*
 - ii. DOXAZOSIN (ORAL)*
 - iii. DUTASTERIDE (ORAL)*
 - iv. FINASTERIDE (ORAL)*
 - v. TAMSULOSIN (ORAL)*
 - vi. TERAZOSIN (ORAL)*
 - b. Grandfathering applies
 - c. The committee voted on the above recommendations

- i. All present committee members voted in favor of the recommendations
- ii. No committee members voted against the recommendations.
- iii. No committee members abstained.
- 9. Calcium Channel Blockers
 - a. Preferred Products
 - i. AMLODIPINE (ORAL)*
 - ii. DILTIAZEM CAPSULE ER (ORAL)*
 - iii. DILTIAZEM TABLET (ORAL)*
 - iv. FELODIPINE ER (ORAL)*
 - v. NIFEDIPINE IR (ORAL)*
 - vi. NIFEDIPINE ER (ORAL)*
 - vii. VERAPAMILCAPSULE ER (ORAL)*
 - viii. VERAPAMILTABLET ER (ORAL)*
 - ix. VERAPAMILTABLET (ORAL)*
 - b. Grandfathering applies
 - c. The committee voted on the above recommendations
 - i. All present committee members voted in favor of the recommendations
 - ii. No committee members voted against the recommendations.
 - iii. No committee members abstained.
- 10. HIV-AIDS
 - a. Preferred Products
 - i. ABACAVIR/LAMIVUDINE (ORAL)*
 - ii. ABACAVIR/LAMIVUDINE/ZIDOVUDINE (ORAL)*
 - iii. ABACAVIR SOLUTION (ORAL)*
 - iv. ABACAVIR TABLET (ORAL)*
 - v. APTIVUS CAPSULE (ORAL)*
 - vi. ATAZANAVIR (ORAL)*
 - vii. ATRIPLA (ORAL)*
 - viii. BIKTARVY (ORAL)*
 - ix. COMPLERA (ORAL)*
 - x. CRIXIVAN (ORAL)*
 - xi. DELSTRIGO (ORAL) NEW
 - xii. DESCOVY (ORAL)*
 - xiii. DIDANOSINE CAPSULE DR (ORAL)*
 - xiv. DOVATO (ORAL) NEW
 - xv. EFAVIRENZ CAPSULE (ORAL)*
 - xvi. EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE (ORAL) NEW
 - xvii. EFAVIRENZ TABLET (ORAL)*
 - xviii. EMTRICITABINE CAPSULE (ORAL)*
 - xix. EMTRIVA SOLUTION (ORAL)*

- Ixiii. ZIDOVUDINE TABLET (ORAL)

Ix. VIREAD POWDER (ORAL)*

- lxi. ZIDOVUDINE CAPSULE (ORAL)* lxii. ZIDOVUDINE SYRUP (ORAL)*

- lix. VIRACEPT (ORAL)*
- Ivii. TRUVADA (ORAL)* lviii. TYBOST (ORAL)*
- lvi. TRIUMEQ (ORAL)*
- IV. TIVICAY PD SUSPENSION (ORAL)-NEW
- liv. TIVICAY (ORAL)*
- liii. TENOFOVIR DISOPROXIL FUMARATE (ORAL)*
- lii. SYMTUZA (ORAL) NEW
- li. STRIBILD (ORAL)*
- I. STAVUDINE CAPSULE (ORAL)*
- xlix. SELZENTRY TABLET (ORAL)*
- xlviii. RITONAVIR TABLET (ORAL)*
- xlvii. REYATAZ POWDER PACK (ORAL)- NEW
- xlvi. PREZISTA ORAL SUSP (ORAL)*
- xlv. PREZISTA (ORAL)*
- xliv. PREZCOBIX (ORAL)*
- xliii. PIFELTRO (ORAL)*
- xlii. ODEFSEY (ORAL)*
- xli. NORVIR SOLUTION (ORAL)*
- xl. NORVIR POWDER PACK (ORAL)-NEW
- xxxix. NEVIRAPINE TABLET (ORAL)*
- xxxviii. NEVIRAPINEORAL SUSP (ORAL)*
- xxxvii. NEVIRAPINEER (ORAL)*
- xxxvi. LOPINAVIR/RITONAVIR TABLET (ORAL)*
- xxxv. LOPINAVIR/RITONAVIR SOLUTION (ORAL)*
- xxxiv. LEXIVA SUSPENSION (ORAL)*
- xxxiii. LAMIVUDINE-ZIDOVUDINE (ORAL)*
- xxxii. LAMIVUDINETABLET (ORAL)*
- xxxi. LAMIVUDINESOLUTION (ORAL)*
- xxx. JULUCA (ORAL)- NEW
- xxix. INVIRASETABLET (ORAL)*
- xxviii. ISENTRESS TAB CHEW (ORAL)*
- xxvii. ISENTRESS POWDER PACK (ORAL)*
- xxvi. ISENTRESS HD (ORAL)- NEW
- xxv. ISENTRESS (ORAL)*
- xxiv. GENVOYA (ORAL)*
- xxiii. FUZEON (SUB-Q)*
- xxii. FOSAMPRENAVIR TABLET (ORAL)*
- xxi. EVOTAZ (ORAL)*
- xx. ETRAVIRINE (ORAL)*

b. Moving to Non-Preferred

- i. Edurant (Oral)
- c. Grandfathering applies
- d. This class will be monitored each quarter for cost and utilization
- e. The committee voted on the above recommendations
 - i. All present committee members voted in favor of the recommendations
 - ii. No committee members voted against the recommendations.
 - iii. No committee members abstained.
- 11. Movement Disorders
 - a. Preferred Products
 - i. AUSTEDO (ORAL) New
 - ii. INGREZZA (ORAL)-New
 - b. The remaining products in this class are recommended as non-preferred
 - c. Grandfathering applies
 - d. The committee voted on the above recommendations
 - i. All present committee members voted in favor of the recommendations
 - ii. No committee members voted against the recommendations.
 - iii. No committee members abstained.

Supplemental Rebate Class Vote

- 1. Continuous Glucose Monitors (CGM)
 - a. Preferred Products
 - i. Diabetes Meters, Continuous
 - 1. DEXCOM G6 CGM SYSTEM (NEW)
 - a. Ages 2 years old to less than 4 years old
 - 2. FREESTYLE LIBRE SYSTEM (NEW)
 - a. Ages 14 and up
 - 3. FREESTYLE LIBRE 2 SYSTEM (NEW)
 - a. Ages 4 years old and up
 - b. The remaining products in this class are recommended non-preferred
 - c. Grandfathering for Guardian products only

- d. The committee voted on the above recommendations
 - i. All present committee members voted in favor of the recommendations
 - ii. No committee members voted against the recommendations.
- iii. No committee members abstained.

New Drug Recommendations and Vote

- 1. Brexafemme
 - a. Recommendation is Non-Preferred
 - i. All present committee members voted in favor of the recommendations
 - ii. No committee members voted against the recommendations.
 - iii. No committee members abstained.
- 2. Kloxxado
 - a. Recommendation is Preferred
 - i. All present committee members voted in favor of the recommendations
 - ii. No committee members voted against the recommendations.
 - iii. No committee members abstained.
- 3. Ponvory
 - a. Recommendation is Non-Preferred
 - i. All present committee members voted in favor of the recommendations
 - ii. No committee members voted against the recommendations.
 - iii. No committee members abstained.
- 4. Qelbree
 - a. Recommendation is Non-Preferred
 - i. All present committee members voted in favor of the recommendations
 - ii. No committee members voted against the recommendations.
 - iii. No committee members abstained.

FUTURE MEETING DATES: JANUARY 19, 2022 ADJOURNMENT

The meeting adjourned at 3:52 PM Minutes recorded by Robin Davis

<u>Swzń Bermany</u> Suzi Berman, RPh Director of Pharmacy Services

Date : January 19, 2022